Response to: Lavey, RS et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IB-IVA carcinoma of the cervix: a Southwest Oncology Group Study. Gynecol. Oncol. 95 (2004) 145-151.
Krafft
Alexander
A
Hess
Thomas
T
D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron; D002945:Cisplatin